ENTEROLACTIS
by SOFAR
ENTEROLACTIS is a premier line of probiotic supplements researched and developed by SOFAR.
The superior product quality and proven efficacy and safety in helping to balance the intestinal microbiota have made the ENTEROLACTISproducts widely known and highly valued by medical professionals and consumers.
Research, innovation
and popularisation of science
At SOFAR, innovation is more than research – it also encompasses popularisation of science. We were among the first to set up an innovative laboratory specialising in the reasearch of the microbiota and probiotics, in partnership with the Kilometro Rosso Science and Technology Park.
Our goal for the laboratory is to be known as a national benchmark for research in this field, promoting the study of new applications and the development of innovative products for human use. ENTEROLACTIS.it continues SOFAR’s commitment in the popularisation of science.
Our history
1968
Founded in 1968 to distribute its own and other companies’ products, SOFAR was immediately recognized for its ability to offer cutting-edge solutions, as well as to respond effectively to doctors’ therapeutic choices and patients’ self-medication requirements.
We began producing our own range of medicines and then expanded production to include dietary supplements and medical devices.
2001
In 2001, through collaborative ventures with various universities, SOFAR launched its range of probiotics, contributing significantly to the foundation of this future dominant supplement category. Our probiotic line quickly became the leading product in the gastroenterology field.
2007
In 2007, SOFAR started its internationalisation programme.
2019
In 2019, we entered into a partnership with the Kilometro Rosso Science and Technology Park in Bergamo to create a laboratory for microbiological testing that seeks to be a benchmark for research in this field.
Our history
1968
Founded in 1968 to distribute its own and other companies’ products, SOFAR was immediately recognized for its ability to offer cutting-edge solutions, as well as to respond effectively to doctors’ therapeutic choices and patients’ self-medication requirements.
We began producing our own range of medicines and then expanded production to include dietary supplements and medical devices.
2001
In 2001, through collaborative ventures with various universities, SOFAR launched its range of probiotics, contributing significantly to the foundation of this future dominant supplement category. Our probiotic line quickly became the leading product in the gastroenterology field.
2007
In 2007, SOFAR began a process of internationalisation.
2019
In 2019, we entered into a partnership with the Kilometro Rosso Science and Technology Park in Bergamo to create a laboratory for microbiological testing that seeks to be a benchmark for research in this field.